NCT00021151View on ClinicalTrials.gov

Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia

NACompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

April 30, 2001

Study Completion Date

May 31, 2002

Conditions
Leukemia
Interventions
BIOLOGICAL

alemtuzumab

Trial Locations (1)

44106-5065

Ireland Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Case Comprehensive Cancer Center

OTHER

NCT00021151 - Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter